Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
news
October 26, 2009
Napo Acquires Rights to Additional CFTR Technology
Napo Acquires Rights to Additional CFTR Technology
October 8, 2009
Napo Gathers International Panel on Global Health
Napo Gathers International Panel on Global Health
August 4, 2009
Napo Pharmaceuticals Completes Dose Selection Phase of ADVENT Trial
Napo Pharmaceuticals Completes Dose Selection Phase of ADVENT Trial
May 27, 2009
Napo Participation in Call to Action to Prevent Deaths from Diarrheal Diseases in Children Under Five Years of Age
Napo Participation in Call to Action to Prevent Deaths from Diarrheal Diseases in Children Under Five Years of Age
May 19, 2009
Napo Pharmaceuticals, Inc. Appoints New Vice-President of Business Development
Napo Pharmaceuticals, Inc. Appoints New Vice-President of Business Development
May 5, 2009
Napo Pharmaceuticals Initiates Preclinical Development of a Novel CFTR Inhibitor Using Preclinical Resources Offered by the National Institute of Allergy and Infectious Diseases (NIAID)
Napo Pharmaceuticals Initiates Preclinical Development of a Novel CFTR Inhibitor Using Preclinical Resources Offered by the National Institute of Allergy and Infectious Diseases (NIAID)
April 30, 2009
Napo Pharmaceuticals Receives Biotech Humanitarian Award Nomination
Napo Pharmaceuticals Receives Biotech Humanitarian Award Nomination
April 8, 2009
Croflemer, First-In-Class Anti-Diarrheal Agent, Positive Clinical Results to be discussed at 13th Annual US-Japan CMSP in Kolkata, India
Croflemer, First-In-Class Anti-Diarrheal Agent, Positive Clinical Results to be discussed at 13th Annual US-Japan CMSP in Kolkata, India
February 3, 2009
Napo Pharmaceuticals Receives Cornerstone Investment for Crofelemer Access Program
Napo Pharmaceuticals Receives Cornerstone Investment for Crofelemer Access Program
If you would like to receive e-mail alerts when we send out press releases, please send an e-mail to news@napopharma.com with the subject 'subscribe'.
